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challenging diagnosisFigure 1 Liver tests evolution since infliximab introduction until
8 months after its withdrawal. Abbreviations: TB: total bilirubin;
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aspartate aminotransferase; ALT: alanine aminotransferase.Dear Sir,
A 24-year-old male patient with a 6-year history of
Crohn's disease (A2L1B2, Montreal classification),1 in remis-
sion for 4 years with mesalazine, was admitted in September
2010 complaining of abdominal pain and cramps. Physical
examination revealed slight and diffuse abdominal pain.
Entero-magnetic resonance revealed terminal ileitis and,
thus, budesonide (9 mg/day) and azathioprine (2.5 mg/kg/
day) were started. Nevertheless, the patient presented 12%
of weight loss in 7 months. In April 2011, abdominal
ultrasound showed persistent bowel loop wall thickening.
Infliximab 5 mg/kg was added to azathioprine in May 2011 and
the patient became rapidly asymptomatic, presenting 10 kg
weight gain. However, since the second infliximab infusion,
liver tests raised: ALP 388 U/L (NR: 38–126 U/L), GGT
339 U/L (NR: 12–58 U/L), AST 167 U/L (NR: 15–46 U/L), ALT
211 U/L (NR: 13–69 U/L). Azathioprine was interrupted in
October 2011. Serological tests for hepatitis A, B and C,
cytomegalovirus, Epstein–Barr virus and herpes simplex
virus were negative. Liver autoimmunity and metabolic
study, abdominal ecodoppler, computerized tomography
andmagnetic resonance cholangiopancreatography were all
normal. A liver biopsy revealed slight, chronic hepatitis and
cholestasis.
Considering the exclusion of main liver diseases (such
as primary sclerosing cholangitis, nodular regenerative hyper-
plasia, autoimmune hepatitis, reactive hepatitis, hepatosplenic
T cell lymphoma, viral hepatitis reactivation, cirrhosis), the
temporal correlation between infliximab exposure and
laboratorial changes, along with a CIOMS/RUCAM score of
8 (reflecting a probable toxic effect of infliximab on the
liver),2 an infliximab-induced hepatitis diagnosis was ad-
mitted. In December 2011, a switch to adalimumab was
made and liver enzyme reached normal values in 8 months
(Fig. 1).
Several drugs used to treat IBD have been implicated in
liver injury, however, relatively few cases of anti-TNF-α
induced hepatitis have been reported.3 In this case, IBD
related hepatobiliary diseases and malignancy were exclud-
ed. Withdrawal of azathioprine was the first option, since
this drug is responsible for most of the cases of hepatotox-
icity in IBD patients. However, liver enzymes remained1873-9946/$ - see front matter © 2013 European Crohn's and Colitis Org
http://dx.doi.org/10.1016/j.crohns.2013.11.013elevated. As there was strong evidence of temporal
relationship between infliximab exposure and elevation of
liver enzymes, a switch to adalimumab was decided,
enabling an uneventful recovery.
Although rare, there are some case reports of infliximab
induced liver injury. Autoimmune phenotype is the most
common, but cholestatic pattern has also been reported.4
Polymorphisms in genes encoding proteins related to TNF-α
seem to modify pharmacodynamics of anti-TNF-α. This fact
may explain different individual response to TNF-α antago-
nists and also distinct patterns of toxicity and absence of
cross-reactivity between these drugs.5
Thus, DILI diagnosis can represent a clinical challenge in
IBD patients, as it, following the exclusion of other causes,
involves a temporal correlation between drug exposure and
appearance of hepatic abnormalities, and its normalization
after treatment withdrawal.
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